免疫系统
浆液性液体
医学
肿瘤微环境
免疫疗法
肿瘤科
浆液性癌
内科学
癌
卵巢癌
癌症研究
癌症
免疫学
作者
Lucy B. Van Kleunen,Mansooreh Ahmadian,Miriam D. Post,Rebecca J. Wolsky,Christian Rickert,Kimberly R. Jordan,Junxiao Hu,Jennifer K. Richer,Lindsay W. Brubaker,Nicole A. Marjon,Kian Behbakht,Matthew J. Sikora,Benjamin G. Bitler,Aaron Clauset
出处
期刊:Cancer immunology research
[American Association for Cancer Research]
日期:2024-08-08
卷期号:: OF1-OF16
标识
DOI:10.1158/2326-6066.cir-23-1109
摘要
Abstract Ovarian cancer is the deadliest gynecologic malignancy, and therapeutic options and mortality rates over the last three decades have largely not changed. Recent studies indicate that the composition of the tumor immune microenvironment (TIME) influences patient outcomes. To improve spatial understanding of the TIME, we performed multiplexed ion beam imaging on 83 human high-grade serous carcinoma tumor samples, identifying approximately 160,000 cells across 23 cell types. From the 77 of these samples that met inclusion criteria, we generated composition features based on cell type proportions, spatial features based on the distances between cell types, and spatial network features representing cell interactions and cell clustering patterns, which we linked to traditional clinical and IHC variables and patient overall survival (OS) and progression-free survival (PFS) outcomes. Among these features, we found several significant univariate correlations, including B-cell contact with M1 macrophages (OS HR = 0.696; P = 0.011; PFS HR = 0.734; P = 0.039). We then used high-dimensional random forest models to evaluate out-of-sample predictive performance for OS and PFS outcomes and to derive relative feature importance scores for each feature. The top model for predicting low or high PFS used TIME composition and spatial features and achieved an average AUC score of 0.71. The results demonstrate the importance of spatial structure in understanding how the TIME contributes to treatment outcomes. Furthermore, the present study provides a generalizable roadmap for spatial analyses of the TIME in ovarian cancer research.
科研通智能强力驱动
Strongly Powered by AbleSci AI